Clinical management of metastatic colorectal cancer in the era of precision medicine
F Ciardiello, D Ciardiello, G Martini… - CA: a cancer journal …, 2022 - Wiley Online Library
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
Immunotherapy in advanced anal cancer: Is the beginning of a new era?
D Ciardiello, LP Guerrera, BA Maiorano… - Cancer Treatment …, 2022 - Elsevier
For decades metastatic squamous cell carcinoma of the anus (SCCA) has been considered
a rare disease with very limited treatment options and a dismal prognosis. Prior to 2017, no …
a rare disease with very limited treatment options and a dismal prognosis. Prior to 2017, no …
Pretreatment plasma circulating tumor DNA RAS/BRAF mutational status in refractory metastatic colorectal cancer patients who are candidates for anti-EGFR …
D Ciardiello, S Napolitano, V Famiglietti, L Esposito… - Cancers, 2023 - mdpi.com
Simple Summary Rechallenge with epidermal growth factor (EGFR) inhibitors represents a
promising therapeutic strategy in patients with refractory RAS/BRAF wild-type metastatic …
promising therapeutic strategy in patients with refractory RAS/BRAF wild-type metastatic …
Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
L Matteucci, A Bittoni, G Gallo, L Ridolfi, A Passardi - Cancers, 2023 - mdpi.com
Simple Summary The majority of metastatic colorectal cancer cases are mismatch-repair-
proficient and microsatellite-stable, and unfortunately this condition is associated with an …
proficient and microsatellite-stable, and unfortunately this condition is associated with an …
[HTML][HTML] Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?
JE Olguin, MG Mendoza-Rodriguez… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is among the most prevalent and deadly neoplasms worldwide.
According to GLOBOCAN predictions, its incidence will increase from 1.15 million CRC …
According to GLOBOCAN predictions, its incidence will increase from 1.15 million CRC …
Serial circulating tumor DNA in monitoring the effect of neoadjuvant and adjuvant immunotherapy in patients with colon cancer: case series and review of the literature
Q Qin, K Yang, T Ma, H Wang, P Yu… - Journal of …, 2022 - journals.lww.com
Although programmed death 1 blockade has significantly improved the survival of advanced
colorectal cancer patients with DNA mismatch repair-deficient (dMMR)/microsatellite …
colorectal cancer patients with DNA mismatch repair-deficient (dMMR)/microsatellite …
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
Despite recent molecular and immunological advancements, prognosis of metastatic
colorectal cancer (mCRC) patients remains poor. In this context, several retrospective and …
colorectal cancer (mCRC) patients remains poor. In this context, several retrospective and …
The interplay between anti-angiogenics and immunotherapy in colorectal cancer
BA Maiorano, A Parisi, E Maiello, D Ciardiello - Life, 2022 - mdpi.com
Simple Summary Colorectal cancer is a frequent and lethal neoplasm. The tumor often
creates new vessels to grow and spread—a process called 'angiogenesis'. Therefore, drugs …
creates new vessels to grow and spread—a process called 'angiogenesis'. Therefore, drugs …
[HTML][HTML] Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
C Cremolini, C Montagut, P Ronga, F Venturini… - Frontiers in …, 2023 - frontiersin.org
In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal
growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option …
growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option …
Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS …
G Martini, D Ciardiello, V Famiglietti, D Rossini… - Cancer …, 2023 - Wiley Online Library
The rechallenge strategy is based on the concept that a subset of patients with RAS wild‐
type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor …
type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor …